Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLINICAL AND NEUROCOGNITIVE EFFECTS OF CLOZAPINE AND RISPERIDONE IN TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS - A PROSPECTIVE-STUDY
Autore:
LINDENMAYER JP; ISKANDER A; PARK M; APERGI FS; CZOBOR P; SMITH R; ALLEN D;
Indirizzi:
MANHATTAN PSYCHIAT CTR,PSYCHOPHARMACOL RES UNIT NEW YORK NY 10035 NYU,SCH MED,NATHAN KLINE INST PSYCHIAT RES NEW YORK NY 00000
Titolo Testata:
The Journal of clinical psychiatry
fascicolo: 10, volume: 59, anno: 1998,
pagine: 521 - 527
SICI:
0160-6689(1998)59:10<521:CANEOC>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PSYCHIATRIC-SYMPTOMS; COGNITIVE FUNCTIONS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Lindenmayer et al., "CLINICAL AND NEUROCOGNITIVE EFFECTS OF CLOZAPINE AND RISPERIDONE IN TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS - A PROSPECTIVE-STUDY", The Journal of clinical psychiatry, 59(10), 1998, pp. 521-527

Abstract

Background: Few controlled studies have compared the efficacy of clozapine and risperidone in treatment-refractory schizophrenic patients. The present study investigates the efficacy of both clozapine and risperidone on psychopathologic and neurocognitive measures in a prospective la-week open-label trial in treatment-refractory schizophrenic patients from state psychiatric hospitals. Method: Thirty-five DSM-IV schizophrenic patients with a documented history of nonresponse to typicalneuroleptics were treated with either clozapine or risperidone. Response was assessed every 2 weeks by independent raters with the Positiveand Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scale, neurologic rating scales, and plasma drug levels. Neurocognitive tests were administered at baseline and week 12. Results: Bothclozapine and risperidone brought about significant (p <.003) overallimprovement in psychopathology. However, clozapine was numerically superior to risperidone on PANSS total scores and PANSS positive, negative, excitement, and cognitive factors. Extrapyramidal side effects were minimal for clozapine, whereas some were present for risperidone. Patients taking risperidone improved significantly in the beginning stages of the study and remained stable thereafter. Patients taking clozapine showed a gradual improvement that occurred over the entire length of the trial. Neurocognitive measures showed minimal improvement and did not differentiate between the 2 medication groups. Conclusion: Bothclozapine and risperidone were comparably effective across a wide spectrum of psychopathologic measures. While the efficacy of clozapine was only numerically superior to that of risperidone, it was associated with fewer extrapyramidal side effects and with progressive improvement over the 12-week treatment period, suggesting that in longer trials clozapine may prove to be superior to risperidone in neuroleptic-refractory patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/01/20 alle ore 19:16:27